{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:02:16Z","timestamp":1791525736830,"version":"4.3.4"},"reference-count":64,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.vaccine.2021.09.067","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T16:21:55Z","timestamp":1633969315000},"page":"6644-6652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Development of a bivalent conjugate vaccine candidate against rotaviral diarrhea and tuberculosis using polysaccharide from Mycobacterium tuberculosis conjugated to \u0394VP8* protein from rotavirus"],"prefix":"10.1016","volume":"39","author":[{"given":"Wook-Jin","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon-Kyung","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngmi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Sun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchirkumar","family":"Pansuriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Nae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeong-Jae","family":"Seok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5945-3969","authenticated-orcid":false,"given":"Ravi","family":"Ganapathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2021.09.067_b0005","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1473-3099(11)70253-5","article-title":"2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis","volume":"12","author":"Tate","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2021.09.067_b0010","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S1473-3099(18)30362-1","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Troeger","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2021.09.067_b0015","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3201\/eid1202.050006","article-title":"Rotavirus and severe childhood diarrhea","volume":"12","author":"Parashar","year":"2006","journal-title":"Emerg Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2021.09.067_b0020","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.4161\/hv.7.12.18321","article-title":"Rotavirus vaccines: update on global impact and future priorities","volume":"7","author":"Yen","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2021.09.067_b0025","unstructured":"WHO. Vaccine in national immunization programme update; 2020."},{"key":"10.1016\/j.vaccine.2021.09.067_b0030","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/cid\/cix369","article-title":"Effectiveness of Rotavirus Vaccination: A Systematic Review of the First Decade of Global Postlicensure Data, 2006\u20132016","volume":"65","author":"Jonesteller","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"9741","key":"10.1016\/j.vaccine.2021.09.067_b0035","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(10)60755-6","article-title":"Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial","volume":"376","author":"Zaman","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.09.067_b0040","first-page":"108","article-title":"Effect of human rotavirus vaccine on severe diarrhea in African infants","volume":"28","author":"Madhi","year":"2016","journal-title":"Malawi Med J"},{"issue":"9741","key":"10.1016\/j.vaccine.2021.09.067_b0045","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(10)60889-6","article-title":"Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial","volume":"376","author":"Armah","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vaccine.2021.09.067_b0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/pathogens6040065","article-title":"Differences of Rotavirus Vaccine Effectiveness by Country: Likely Causes and Contributing Factors","volume":"6","author":"Desselberger","year":"2017","journal-title":"Pathogens"},{"issue":"10","key":"10.1016\/j.vaccine.2021.09.067_b0055","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1080\/21645515.2016.1197452","article-title":"Rotavirus vaccination and intussusception - Science, surveillance, and safety: A review of evidence and recommendations for future research priorities in low and middle income countries","volume":"12","author":"Yen","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"10.1016\/j.vaccine.2021.09.067_b0060","doi-asserted-by":"crossref","first-page":"e898","DOI":"10.1016\/S2214-109X(17)30289-9","article-title":"The global burden of tuberculosis mortality in children: a mathematical modelling study","volume":"5","author":"Dodd","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"8986","key":"10.1016\/j.vaccine.2021.09.067_b0065","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(95)92348-9","article-title":"Variation in protection by BCG: implications of and for heterologous immunity","volume":"346","author":"Fine","year":"1995","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2021.09.067_b0070","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/ije\/22.6.1154","article-title":"Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis","volume":"22","author":"Rodrigues","year":"1993","journal-title":"Int J Epidemiol"},{"issue":"6257","key":"10.1016\/j.vaccine.2021.09.067_b0075","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/343476a0","article-title":"Localization of VP4 neutralization sites in rotavirus by three-dimensional cryo-electron microscopy","volume":"343","author":"Prasad","year":"1990","journal-title":"Nature"},{"issue":"43","key":"10.1016\/j.vaccine.2021.09.067_b0080","doi-asserted-by":"crossref","first-page":"6121","DOI":"10.1016\/j.vaccine.2012.07.078","article-title":"Construction and characterization of human rotavirus recombinant VP8* subunit parenteral vaccine candidates","volume":"30","author":"Wen","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.09.067_b0085","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1016\/j.vaccine.2014.06.060","article-title":"Inclusion of a universal tetanus toxoid CD4(+) T cell epitope P2 significantly enhanced the immunogenicity of recombinant rotavirus DeltaVP8* subunit parenteral vaccines","volume":"32","author":"Wen","year":"2014","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2021.09.067_b0090","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1128\/JVI.01835-10","article-title":"Norovirus P particle, a novel platform for vaccine development and antibody production","volume":"85","author":"Tan","year":"2011","journal-title":"J Virol"},{"issue":"11","key":"10.1016\/j.vaccine.2021.09.067_b0095","doi-asserted-by":"crossref","first-page":"10665","DOI":"10.1021\/acsnano.8b02776","article-title":"Bioengineered Norovirus S60 Nanoparticles as a Multifunctional Vaccine Platform","volume":"12","author":"Xia","year":"2018","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.vaccine.2021.09.067_b0100","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1473-3099(17)30242-6","article-title":"Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial","volume":"17","author":"Groome","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2021.09.067_b0105","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S1473-3099(20)30001-3","article-title":"Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Groome","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2021.09.067_b0110","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrd3012","article-title":"Carbohydrate vaccines: developing sweet solutions to sticky situations?","volume":"9","author":"Astronomo","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"140","key":"10.1016\/j.vaccine.2021.09.067_b0115","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/newbio245012a0","article-title":"B cell mitogenic properties of thymus-independent antigens","volume":"245","author":"Coutinho","year":"1973","journal-title":"Nat New Biol"},{"key":"10.1016\/j.vaccine.2021.09.067_b0120","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0065-3101(24)00217-2","article-title":"Human immune responses to polysaccharide antigens: an analysis of bacterial polysaccharide vaccines in infants","volume":"32","author":"Barrett","year":"1985","journal-title":"Adv Pediatr"},{"issue":"1","key":"10.1016\/j.vaccine.2021.09.067_b0125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1146\/annurev-immunol-030409-101159","article-title":"How bacterial carbohydrates influence the adaptive immune system","volume":"28","author":"Avci","year":"2010","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2021.09.067_b0130","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1084\/jem.50.4.533","article-title":"Chemo-Immunological Studies on Conjugated Carbohydrate-Proteins : Ii. Immunological Specificity of Synthetic Sugar-Protein Antigens","volume":"50","author":"Avery","year":"1929","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.09.067_b0135","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1084\/jem.50.4.521","article-title":"Chemo-immunological studies on conjugated carbohydrate-proteins: I. The synthesis ofp-Aminophenol beta-Glucoside, p-Aminophenol beta-Galactoside, and their coupling with serum globulin","volume":"50","author":"Goebel","year":"1929","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.vaccine.2021.09.067_b0140","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1054\/tuld.1998.0200","article-title":"The capsule of Mycobacterium tuberculosis and its implications for pathogenicity","volume":"79","author":"Daff\u00e9","year":"1999","journal-title":"Tuber Lung Dis"},{"key":"10.1016\/j.vaccine.2021.09.067_b0145","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1042\/BCJ20190324","article-title":"The Mycobacterium tuberculosis capsule: a cell structure with key implications in pathogenesis","volume":"476","author":"Kalscheuer","year":"2019","journal-title":"Biochem J"},{"issue":"2","key":"10.1016\/j.vaccine.2021.09.067_b0150","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/glycob\/8.2.113","article-title":"Mycobacterial lipoarabinomannan: an extraordinary lipoheteroglycan with profound physiological effects","volume":"8","author":"Chatterjee","year":"1998","journal-title":"Glycobiology"},{"issue":"9","key":"10.1016\/j.vaccine.2021.09.067_b0155","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.1016\/S0021-9258(18)42685-3","article-title":"Lipoarabinomannan. Multiglycosylated form of the mycobacterial mannosylphosphatidylinositols","volume":"267","author":"Chatterjee","year":"1992","journal-title":"J Biol Chem"},{"issue":"15","key":"10.1016\/j.vaccine.2021.09.067_b0160","doi-asserted-by":"crossref","first-page":"9652","DOI":"10.1016\/S0021-9258(18)92870-X","article-title":"Structural features of the arabinan component of the lipoarabinomannan of Mycobacterium tuberculosis","volume":"266","author":"Chatterjee","year":"1991","journal-title":"J Biol Chem"},{"issue":"Pt 2","key":"10.1016\/j.vaccine.2021.09.067_b0165","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1042\/bj2970351","article-title":"Structural features of the exocellular polysaccharides of Mycobacterium tuberculosis","volume":"297","author":"Lemassu","year":"1994","journal-title":"Biochem J"},{"key":"10.1016\/j.vaccine.2021.09.067_b0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006250","article-title":"Enhanced control of Mycobacterium tuberculosis extrapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine","volume":"13","author":"Prados-Rosales","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2021.09.067_b0175","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1016\/S0264-410X(99)00124-3","article-title":"Synthesis and immunologic characterisation of Mycobacterium tuberculosis lipoarabinomannan specific oligosaccharide-protein conjugates","volume":"17","author":"Hamasur","year":"1999","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2021.09.067_b0180","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1128\/IAI.70.5.2566-2575.2002","article-title":"Glucan is a component of the Mycobacterium tuberculosis surface that is expressed in vitro and in vivo","volume":"70","author":"Schwebach","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2021.09.067_b0185","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1172\/JCI128459","article-title":"Capsular glycan recognition provides antibody-mediated immunity against tuberculosis","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"issue":"25","key":"10.1016\/j.vaccine.2021.09.067_b0190","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1016\/j.vaccine.2017.04.078","article-title":"Polysaccharide conjugate vaccine protein carriers as a \u201cneglected valency\u201d - Potential and limitations","volume":"35","author":"Br\u00f6ker","year":"2017","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2021.09.067_b0195","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/nm.2535","article-title":"A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design","volume":"17","author":"Avci","year":"2011","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.vaccine.2021.09.067_b0200","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/0264-410X(94)90237-2","article-title":"Enhanced immunogenicity of protein-dextran conjugates: I. Rapid stimulation of enhanced antibody responses to poorly immunogenic molecules","volume":"12","author":"Lees","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.09.067_b0205","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/glycob\/cwn031","article-title":"Comparative structural analyses of the alpha-glucan and glycogen from Mycobacterium bovis","volume":"18","author":"Dinadayala","year":"2008","journal-title":"Glycobiology"},{"key":"10.1016\/j.vaccine.2021.09.067_b0210","doi-asserted-by":"crossref","first-page":"23094","DOI":"10.1074\/jbc.272.37.23094","article-title":"The phosphatidyl-myo-inositol anchor of the lipoarabinomannans from Mycobacterium bovis bacillus Calmette Guerin. Heterogeneity, structure, and role in the regulation of cytokine secretion","volume":"272","author":"Nigou","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2021.09.067_b0215","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0264-410X(99)00370-9","article-title":"Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) for use in protein-polysaccharide conjugate vaccines and immunological reagents. II. Selective crosslinking of proteins to CDAP-activated polysaccharides","volume":"18","author":"Shafer","year":"2000","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2021.09.067_b0220","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/0264-410X(95)00195-7","article-title":"Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents","volume":"14","author":"Lees","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.09.067_b0225","first-page":"8","article-title":"Activation of Soluble Polysaccharides with 1-Cyano-4-Dimethylaminopyridine Tetrafluoroborate (CDAP) for Use in Protein-Polysaccharide Conjugate Vaccines and Immunological Reagents. III Optimization of CDAP Activation","author":"Lees","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"10.1016\/j.vaccine.2021.09.067_b0230","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/infdis\/149.5.694","article-title":"Serotypic similarity and diversity of rotaviruses of mammalian and avian origin as studied by plaque-reduction neutralization","volume":"149","author":"Hoshino","year":"1984","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.09.067_b0235","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MGM2-0021-2013","article-title":"Genetics of Capsular Polysaccharides and Cell Envelope (Glyco)lipids","volume":"2","author":"Daffe","year":"2014","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.vaccine.2021.09.067_b0240","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-1-59745-207-6_3","article-title":"Lipoglycans of Mycobacterium tuberculosis: isolation, purification, and characterization","volume":"465","author":"Shi","year":"2009","journal-title":"Methods Mol Biol"},{"issue":"46","key":"10.1016\/j.vaccine.2021.09.067_b0245","doi-asserted-by":"crossref","first-page":"17973","DOI":"10.1073\/pnas.0807761105","article-title":"Lipoarabinomannan of Mycobacterium: mannose capping by a multifunctional terminal mannosyltransferase","volume":"105","author":"Kaur","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2021.09.067_b0250","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.3389\/fimmu.2019.01968","article-title":"Lipoarabinomannan in Active and Passive Protection Against Tuberculosis","volume":"10","author":"Correia-Neves","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2021.09.067_b0255","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1074\/jbc.M004010200","article-title":"Variation in mannose-capped terminal arabinan motifs of lipoarabinomannans from clinical isolates of Mycobacterium tuberculosis and Mycobacterium avium complex","volume":"276","author":"Khoo","year":"2001","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.vaccine.2021.09.067_b0260","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev.immunol.021908.132703","article-title":"Cell-mediated immune responses in tuberculosis","volume":"27","author":"Cooper","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2021.09.067_b0265","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.coi.2018.04.004","article-title":"Updates on antibody functions in Mycobacterium tuberculosis infection and their relevance for developing a vaccine against tuberculosis","volume":"53","author":"Achkar","year":"2018","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.09.067_b0270","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.chom.2013.02.009","article-title":"Antibody-mediated immunity against tuberculosis: implications for vaccine development","volume":"13","author":"Achkar","year":"2013","journal-title":"Cell Host Microbe"},{"issue":"2","key":"10.1016\/j.vaccine.2021.09.067_b0275","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1128\/CVI.05550-11","article-title":"Comparative evaluation of profiles of antibodies to mycobacterial capsular polysaccharides in tuberculosis patients and controls stratified by HIV status","volume":"19","author":"Yu","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2021.09.067_b0280","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00520-19","article-title":"Glycoconjugates: What It Would Take To Master These Well-Known yet Little-Understood Immunogens for Vaccine Development","volume":"4","author":"Avci","year":"2019","journal-title":"mSphere"},{"issue":"2","key":"10.1016\/j.vaccine.2021.09.067_b0285","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.smim.2013.05.005","article-title":"Carbohydrates and T cells: a sweet twosome","volume":"25","author":"Avci","year":"2013","journal-title":"Semin Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2021.09.067_b0290","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2006.08.021","article-title":"Bacterial glycans: key mediators of diverse host immune responses","volume":"126","author":"Comstock","year":"2006","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.vaccine.2021.09.067_b0295","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.vaccine.2009.01.005","article-title":"The influence of carrier protein on the immunogenicity of simultaneously administered conjugate vaccines in infants","volume":"27","author":"P\u00f6llabauer","year":"2009","journal-title":"Vaccine"},{"issue":"43","key":"10.1016\/j.vaccine.2021.09.067_b0300","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1016\/j.vaccine.2014.08.041","article-title":"Preparation and testing of a Vi conjugate vaccine using pneumococcal surface protein A (PspA) from Streptococcus pneumoniae as the carrier protein","volume":"32","author":"Kothari","year":"2014","journal-title":"Vaccine"},{"issue":"21","key":"10.1016\/j.vaccine.2021.09.067_b0305","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1016\/j.vaccine.2018.04.035","article-title":"Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever","volume":"36","author":"An","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.09.067_b0310","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.4049\/jimmunol.157.6.2229","article-title":"A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens","volume":"157","author":"Snapper","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2021.09.067_b0315","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1080\/21645515.2016.1204501","article-title":"Immunogenicity and protective efficacy of rotavirus VP8* fused to cholera toxin B subunit in a mouse model","volume":"12","author":"Xue","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.09.067_b0320","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3389\/fchem.2020.00284","article-title":"Carbohydrate Conjugates in Vaccine Developments","volume":"8","author":"Lang","year":"2020","journal-title":"Front Chem"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21012822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21012822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:02:19Z","timestamp":1759402939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21012822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":64,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0264410X21012822"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.09.067","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a bivalent conjugate vaccine candidate against rotaviral diarrhea and tuberculosis using polysaccharide from Mycobacterium tuberculosis conjugated to \u0394VP8* protein from rotavirus","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.09.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}